Beneficial effects of a pyrroloquinolinequinone-containing dietary formulation on motor deficiency, cognitive decline and mitochondrial dysfunction in a mouse model of Alzheimer's disease

Heliyon

Volumn 3, Issue 4, 2017, Pages

  Sawmiller, Darrell ^a,b   Li, Song ^b,c   Mori, Takashi ^d   Habib, Ahsan ^b   Rongo, David ^b   Delic, Vedad ^e   Bradshaw, Patrick C ^e   Shytle, R Douglas ^b   Sanberg, Cyndy ^f   Bickford, Paula ^a,b   Tan, Jun ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c DALIAN MEDICAL UNIVERSITY   (China)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f Saneron CCEL Therapeutics Inc   (United States)

Author keywords

Neuroscience

Indexed keywords

EID: 85017366520     PISSN: 24058440     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.heliyon.2017.e00279     Document Type: Article

References (41)

1. [1] Smith, C.D., et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. U S A 88:23 (1991), 10540–10543.
2. [2] Goedert, M., Tau protein and the neurofibrillary pathology of Alzheimer's disease. Ann. N Y Acad. Sci. 777 (1996), 121–131.
3. [3] Golde, T.E., Eckman, C.B., Younkin, S.G., Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim. Biophys. Acta 1502:1 (2000), 172–187.
4. [4] Selkoe, D.J., et al. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann. N Y Acad. Sci. 777 (1996), 57–64.
5. [5] Casley, C.S., et al. Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem. 80:1 (2002), 91–100.
6. [6] Chang, S., et al. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc. Natl. Acad. Sci. U S A 102:51 (2005), 18694–18699.
7. [7] Zhao, Y., Zhao, B., Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid. Med. Cell. Longev., 2013, 2013, 316523.
8. [8] Lin, M.T., Beal, M.F., Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:7113 (2006), 787–795.
9. [9] Moreira, P.I., et al. Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim. Biophys. Acta 1802:1 (2010), 2–10.
10. [10] Dragicevic, N., et al. Green tea epigallocatechin-3-gallate (EGCG) and other flavonoids reduce Alzheimer's amyloid-induced mitochondrial dysfunction. J. Alzheimers Dis. 26:3 (2011), 507–521.
11. [11] Rezai-Zadeh, K., et al. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res. 1214 (2008), 177–187.
12. [12] Rezai-Zadeh, K., et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 25:38 (2005), 8807–8814.
13. [13] Joseph, J.A., Shukitt-Hale, B., Casadesus, G., Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds. Am. J. Clin. Nutr. 81:Suppl. 1 (2005), 313S–316S.
14. [14] Arts, I.C., Hollman, P.C., Polyphenols and disease risk in epidemiologic studies. Am. J. Clin. Nutr. 81:Suppl. 1 (2005), 317S–325S.
15. [15] Darvesh, A.S., et al. Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents. Expert Rev. Neurother. 10:5 (2010), 729–745.
16. [16] Bickford, P.C., et al. Nutraceuticals synergistically promote proliferation of human stem cells. Stem Cells Dev. 15:1 (2006), 118–123.
17. [17] Acosta, S., et al. NT-020, a natural therapeutic approach to optimize spatial memory performance and increase neural progenitor cell proliferation and decrease inflammation in the aged rat. Rejuvenation Res. 13:5 (2010), 581–588.
18. [18] Small, B.J., et al. Nutraceutical intervention improves older adults' cognitive functioning. Rejuvenation Res. 17:1 (2014), 27–32.
19. [19] Bachstetter, A.D., et al. Spirulina promotes stem cell genesis and protects against LPS induced declines in neural stem cell proliferation. PLoS One, 5(5), 2010, e10496.
20. [20] Oakley, H., et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26:40 (2006), 10129–10140.
21. [21] Rucker, R., Chowanadisai, W., Nakano, M., Potential physiological importance of pyrroloquinoline quinone. Altern. Med. Rev. 14:3 (2009), 268–277.
22. [22] Misra, H.S., Rajpurohit, Y.S., Khairnar, N.P., Pyrroloquinoline-quinone and its versatile roles in biological processes. J. Biosci. 37:2 (2012), 313–325.
23. [23] Rae, E.A., Brown, R.E., The problem of genotype and sex differences in life expectancy in transgenic AD mice. Neurosci. Biobehav. Rev. 57 (2015), 238–251.
24. [24] Buchman, A.S., Bennett, D.A., Loss of motor function in preclinical Alzheimer's disease. Expert. Rev. Neurother. 11:5 (2011), 665–676.
25. [25] Jawhar, S., et al. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 33:1 (2012), e29–e40.
26. [26] Wang, C., et al. Free radical scavenging activity and neuroprotective potentials of D138, one Cu(II)/Zn(II) Schiff-base complex derived from N,N'-bis(2-hydroxynaphthylmethylidene)-1,3-propanediamine. Neurochem. Res. 39:9 (2014), 1834–1844.
27. [27] Li, S., et al. Swedish mutant APP-based BACE1 binding site peptide reduces APP beta-cleavage and cerebral Abeta levels in Alzheimer's mice. Sci. Rep., 5, 2015, 11322.
28. [28] Rogers, J.T., et al. CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity. J. Neurosci. 31:45 (2011), 16241–16250.
29. [29] Dragicevic, N., et al. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J. Alzheimers Dis. 20:Suppl. 2 (2010), S535–S550.
30. [30] Brown, M.R., Geddes, J.W., Sullivan, P.G., B rain region-specific, age-related, alterations in mitochondrial responses to elevated calcium. J. Bioenerg. Biomembr. 36:4 (2004), 401–406.
31. [31] Mori, T., et al. Tannic Acid Is a Natural beta-Secretase Inhibitor That Prevents Cognitive Impairment and Mitigates Alzheimer-like Pathology in Transgenic Mice. J. Biol. Chem. 287:9 (2012), 6912–6927.
32. [32] Stites, T.E., Mitchell, A.E., Rucker, R.B., Physiological importance of quinoenzymes and the O-quinone family of cofactors. J. Nutr. 130:4 (2000), 719–727.
33. [33] Jensen, F.E., et al. The putative essential nutrient pyrroloquinoline quinone is neuroprotective in a rodent model of hypoxic/ischemic brain injury. Neuroscience 62:2 (1994), 399–406.
34. [34] Zhang, L., et al. The neuroprotective effect of pyrroloquinoline quinone on traumatic brain injury. J. Neurotrauma 29:5 (2012), 851–864.
35. [35] Aizenman, E., et al. Interaction of the putative essential nutrient pyrroloquinoline quinone with the N-methyl-D-aspartate receptor redox modulatory site. J. Neurosci. 12:6 (1992), 2362–2369.
36. [36] Hirakawa, A., et al. Pyrroloquinoline quinone attenuates iNOS gene expression in the injured spinal cord. Biochem. Biophys. Res. Commun. 378:2 (2009), 308–312.
37. [37] Guan, S., et al. Pyrroloquinoline quinone against glutamate-induced neurotoxicity in cultured neural stem and progenitor cells. Int. J. Dev. Neurosci. 42 (2015), 37–45.
38. [38] Zhang, J.J., Zhang, R.F., Meng, X.K., Protective effect of pyrroloquinoline quinone against Abeta-induced neurotoxicity in human neuroblastoma SH-SY5Y cells. Neurosci. Lett. 464:3 (2009), 165–169.
39. [39] Zhang, Q., et al. Neuroprotective effects of pyrroloquinoline quinone against rotenone injury in primary cultured midbrain neurons and in a rat model of Parkinson's disease. Neuropharmacology 108 (2016), 238–251.
40. [40] Zhang, Q., et al. Involvement of ERK1/2 pathway in neuroprotective effects of pyrroloquinoline quinine against rotenone-induced SH-SY5Y cell injury. Neuroscience 270 (2014), 183–191.
41. [41] Dumont, M., et al. PGC-1alpha overexpression exacerbates beta-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease. FASEB J. 28:4 (2014), 1745–1755.